PMID- 20425388
OWN - NLM
STAT- MEDLINE
DCOM- 20100806
LR  - 20211020
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 2
IP  - 1
DP  - 2007 Feb
TI  - Prognostic factors in chronic lymphocytic leukemia.
PG  - 49-55
LID - 10.1007/s11899-007-0007-1 [doi]
AB  - Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which 
      individual outcomes range from no need for therapeutic intervention to very 
      aggressive, nonresponding disease. The ability to develop clear, sound prognostic 
      information that permits reliable counsel must be our goal. A combination of 
      easily obtainable, traditional prognostic parameters (bone marrow infiltration 
      patterns, beta-2 microglobulin) along with the clinical Rai stage is still 
      frequently used in the initial risk stratification of patients with CLL. However, 
      novel parameters such as defects detectable on fluorescence in situ hybridization 
      (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain 
      variable region status can add significant prognostic information about a given 
      patient with CLL. How to incorporate these newer tests within the context of the 
      more traditional parameters for a patient with a new diagnosis is the focus of 
      significant continuing research. The outcome of this research has implications 
      for predicting clinical progression rates and the response and duration of 
      response to therapy, as well as for highlighting high-risk patients who will need 
      earlier or more specific treatment approaches.
FAU - Kay, Neil E
AU  - Kay NE
AD  - Mayo Clinic, Stabile 6-28, 200 First Street SW, Rochester, MN 55905, USA. 
      kay.neil@mayo.edu
FAU - Shanafelt, Tait D
AU  - Shanafelt TD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (beta 2-Microglobulin)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 2.7.10.2 (ZAP70 protein, human)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/analysis
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - Bone Marrow/pathology
MH  - Chromosome Aberrations
MH  - Cohort Studies
MH  - Female
MH  - Gene Rearrangement, B-Lymphocyte, Heavy Chain
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Precursor Cell Lymphoblastic 
      Leukemia-Lymphoma/blood/genetics/*mortality/pathology
MH  - Prognosis
MH  - Thymidine Kinase/blood
MH  - ZAP-70 Protein-Tyrosine Kinase/blood
MH  - beta 2-Microglobulin/analysis
RF  - 43
EDAT- 2007/02/01 00:00
MHDA- 2010/08/07 06:00
CRDT- 2010/04/29 06:00
PHST- 2010/04/29 06:00 [entrez]
PHST- 2007/02/01 00:00 [pubmed]
PHST- 2010/08/07 06:00 [medline]
AID - 10.1007/s11899-007-0007-1 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2007 Feb;2(1):49-55. doi: 10.1007/s11899-007-0007-1.